Four different approaches have been selected: firstly, modulating the tumor microenvironment (cytokine modulation, extracellular matrix); second, manipulating the fecal microbiome (use of fecal microbiota transplantation, vancomycin); third, targeting immunogenic tumor peptides (TLR); and lastly, cellular therapies (HER2, NK cells). Here, ERBB2 is linked to neoplasm.